3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neuroblastoma
2
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Glioblastoma
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor Cancer
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Mesothelial Neoplasm
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Liver Diseases
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Interventions
Temozolomide
30
Radiotherapy
23
Filgrastim
12
Carmustine
12
Irinotecan
11
Carboplatin
11
Chemotherapy, Adjuvant
9
O(6)-benzylguanine
8
Etoposide
7
Surgical Procedures, Operative
6
Magnetic Resonance Spectroscopy
6
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Granulocyte Colony-Stimulating Factor
5
Cyclophosphamide
5
sargramostim
4
motexafin gadolinium
4
Topotecan
4
Thiotepa
4
Paclitaxel
4
Melphalan
4
Gene Expression Profiling
4
Gemcitabine
4
Drug Therapy
4
Busulfan
4
temsirolimus
3
etoposide phosphate
3
Specimen Handling
3
Mass Spectrometry
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Central Nervous System Neoplasms
×
Immunotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled